Products
The most comprehensive panel of fully automated Hemostasis assays, designed for disease-state management. From routine to specialty testing, HemosIL reagents deliver fast, accurate results. Robust offering of liquid, ready-to-use assays enhance efficiency of lab operations and ultimately, patient care.
Standardized and automated, delivering fast, reliable results.
Broadest liquid, ready-to-use portfolio for quality and efficiency
We offer more liquid, ready-to-use Hemostasis assays than any other manufacturer. A typical lab can meet 91% of its Hemostasis testing needs, with HemosIL liquid, ready-to-use assays, including PT, APTT, D-Dimer and Antithrombin. Eliminating reconstitution time, acclimation time and repetitive manual pipetting, leads to greater efficiency and better patient care. And, HemosIL assays enhance management of disease-states, from Heparin-Induced Thromobcytopenia and Antiphospholipid Syndrome, to von Willebrand Disease, Thrombophila, and more.
The broadest menu of liquid, ready-to-use Hemostasis assays
HemosIL Reagents
HemosIL Reagents
Broad assay menu for tailored testing
HemosIL PT reagents offer consistent performance sensitivity to enable optimal monitoring of oral anticoagulant therapy and evaluation of the extrinsic coagulation pathway. Highly stable and always consistent for moderate to high sensitivity. HemosIL APTT reagents enable optimal monitoring of therapeutic coagulation inhibitors and screening of the intrinsic coagulation pathyway with excellent sensitivity and lot-to-lot consistency. The General Screening Panel also includes Fibrinogen assays to assess bleeding risk in patients with unexplained prolonged PT or APTT results.
Consistency, test after test, for optimal efficiency.
Fully automated for the timely exclusion of VTE
HemosIL D-Dimer assays are clinically validated with cut-off values for the exclusion of venous thromboembolism (VTE), including both pulmonary embolism (PE) and deep vein thrombosis (DVT), in conjunction with a pretest probability assessment. This approach can reduce the need for costly and invasive imaging tests, typical in the diagnosis of VTE. HemosIL D-Dimer assays offer reliable results in minutes, are highly specific, and fully automated on ACL testing systems, optimizing laboratory workflow.
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
HemosIL Lupus Anticoagulant (LA) Assay Panel
Guidelines for LA testing call for two types of tests, Dilute Russell Viper Venom Test (dRVVT) and an
APTT-based assay with a silica activator. Only IL offers both tests in a single, fully automated panel.
HemosIL AcuStar Antiphospholipid Assay Panel
Complete your automated APS testing with HemosIL AcuStar specialty reagents on the ACL AcuStar testing system.
HemosIL Product
AcuStar Anti-β2 Glycoprotein-I IgG Controls**
PART NUMBER
0009802112
Document
HemosIL Product
AcuStar Anti-β2 Glycoprotein-I IgM Controls **
PART NUMBER
0009802116
Document
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
HIT Testing in Minutes
The first on-demand fully automated assays for HIT antibody detection on Hemostasis systems.
Simple, fully automated and ready to use, results are available in minutes, and on-demand 24/7.
Detects anti-Platelet Factor 4-heparin (anti-PF4-H) antibodies for analytical excellence in agreement with ELISA methods. Reduces staff time and costs and enhances patient management decisions. Assays available for ACL TOP systems, as well as ACL AcuStar systems.*
The on-demand solution that saves more than time.
*AcuStar HIT-IgG not 510(k) cleared. Not available in all countries.
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
Simply complete
All von Willebrand Factor (VWF) assays are fully automated with rapid time to result (<12 minutes), excellent onboard stability and correlation with existing methods. Activity, antigen and factor deficiency detection for complete VWD investigation. Assay panels available for ACL TOP systems, as well as ACL AcuStar systems.
HemosIL Product
AcuStar von Willebrand Factor: Ag [*][**]
PART NUMBER
0009802020
Document
HemosIL Product
AcuStar von Willebrand Factor: CB [*][**]
PART NUMBER
0009802044
Document
HemosIL Product
AcuStar von Willebrand Factor: Controls [*][**]
PART NUMBER
0009802119
Document
HemosIL Product
AcuStar von Willebrand Factor: RCo [*][**]
PART NUMBER
0009802024
Document
HemosIL Product
von Willebrand Factor Ristocetin Cofactor *
PART NUMBER
0020300900
Document
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
Comprehensive and simple detection of fibrinolytic disorders
Fully automated and easy to use, the HemosIL Fibrinolysis Assay Panel includes liquid, ready-to-use FDP assay* with innovative immunoassaythat mitigates fibrinogen interference, Plasminogen assay, and Plasminogen Inhibitor assay, capable of detecting homozygous plasmin-inhibitor-deficiency.
*Not 510(k)-cleared. Not available in all countries.
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
Specialty testing as simple as routine
Antithrombin (AT)
HemosIL Liquid AT is the only ready-to-use AT assay and features enhanced reagent stability and improved onboard stability. Convenient to use and available in three kit sizes to address all test volume requirements.
Homocysteine
The first fully automated, immunoturbidimetric assay for Hemostasis testing. Featuring linearity up to 60 µmol/L, the assay is designed for use with citrated plasma and can be incorporated into a thrombophilia panel.
Protein C Pathway
Includes Protein C and S, as well as a chromogenic Protein C assay (activity), all with excellent stability, linearity and specificity. Free Protein S reagent features the affinity of a polyclonal antibody and the specificity of a monoclonal antibody for enhanced analytical performance.
Activated Protein C (APC) Resistance
Includes a patented test for APC resistance caused by the Factor V:Q506 mutation that allows highly specific FV Leiden detection with >99% sensitivity. Test results not affected by oral anticoagulant or heparin present in plasma samples (up to 1 U/mL).
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
Comprehensive, easy and efficient
Spanning the entire coagulation cascade, these deficient plasmas are used in combination with a selected PT and APTT reagent for the determination of specific Factor activity in citrated plasma on ACL TOP systems. Includes a complete range of immunodepleted factor deficiency plasmas with < 1% residual activity and 24-hour onboard stability, reducing reagent waste. Liquid, ready-to-use FXIII Antigen is fully automated, adding convenience vs manual, less specific clot-solubility method.
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
Note: FXIII assays are exempt from 510(k) clearance.
For testing on ACL TOP and ACL AcuStar Systems
Normal and abnormal controls are available for all HemosIL assays, including both assayed and unassayed formats, and special tests. Assayed Control plasmas have excellent 24-hour stability. Controls for ACL AcuStars assays also available.
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.
* Not 510(k) cleared. Not available in all countries.
** Chemiluminescent technology assay. For Use on ACL AcuStar Hemostasis Testing System.